FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213307792> ?p ?o ?g. }

• W4213307792 endingPage "TPS582" @default.
• W4213307792 startingPage "TPS582" @default.
• W4213307792 abstract "TPS582 Background: Treatment options are limited for pts with LA unresectable or mUC who progress after prior PLT-based and CPI therapies. SG is an antibody-drug conjugate (ADC) composed of an anti-trophopblast cell surface antigen 2 (Trop-2) antibody coupled to SN-38 (a topoisomerase-I inhibitor) via a proprietary hydrolyzable linker. In the phase 2 registrational study TROPHY-U-01 (NCT03547973), SG demonstrated an objective response rate (ORR) of 27% and median overall survival (OS) of 10.9 months in pts with mUC who progressed after prior PLT-based and CPI therapies (n = 113; median, 3 prior lines of therapy; 84% with ≥1 Bellmunt risk factors; Tagawa et al, J Clin Oncol. 2021). These results compared favorably with historic data for single-agent chemotherapy (ORR, ̃18%; OS, 9 months; Powles et al. J Clin Oncol. 2021) and led to accelerated approval of SG by the US Food and Drug Administration for pts with LA or mUC who previously received a PLT-containing chemotherapy and CPI. The phase 3 TROPiCS-04 trial has been initiated to confirm these findings. Methods: TROPiCS-04 (NCT04527991) is a global, multicenter, open-label, randomized, controlled trial in pts with LA unresectable or mUC who progressed after prior PLT-based and CPI therapies. Key eligibility requirements include Eastern Cooperative Oncology Group performance status 0-1; no prior CPI or ADC therapy within 4 weeks of study drug initiation; no history of active interstitial lung disease or noninfectious pneumonitis; and adequate hematologic, hepatic, and renal function. Pts will be randomly assigned 1:1 to receive SG 10 mg/kg intravenously (IV) on days 1 and 8 of 21-day cycles or single-agent treatment of physician’s choice (paclitaxel 175 mg/m 2 , docetaxel 75 mg/m 2 , or vinflunine 320 mg/m 2 IV on day 1 of 21-day cycles) until progressive disease, unacceptable toxicity, or withdrawal of consent. Treatment beyond progressive disease may be permitted in pts deemed to be receiving clinical benefit per investigator assessment. Approximately 600 pts will be enrolled across ̃280 sites in 3 regions (North America, Europe, and Asia-Pacific) to provide 90% power on the primary endpoint of OS. Secondary endpoints include progression-free survival, ORR, clinical benefit rate, duration of response (all per Response Evaluation Criteria in Solid Tumors version 1.1 by blinded independent central review and investigator assessment), safety, and quality of life. Study enrollment started in January 2021 and is ongoing with pts currently enrolled at 30 sites across all 3 regions. Clinical trial information: NCT04527991." @default.
• W4213307792 created "2022-02-24" @default.
• W4213307792 creator A5004985848 @default.
• W4213307792 creator A5007663088 @default.
• W4213307792 creator A5009459069 @default.
• W4213307792 creator A5018733361 @default.
• W4213307792 creator A5019000637 @default.
• W4213307792 creator A5026717218 @default.
• W4213307792 creator A5027991868 @default.
• W4213307792 creator A5036620887 @default.
• W4213307792 creator A5039540735 @default.
• W4213307792 creator A5044972820 @default.
• W4213307792 creator A5051250922 @default.
• W4213307792 creator A5074756323 @default.
• W4213307792 creator A5075511405 @default.
• W4213307792 creator A5083331837 @default.
• W4213307792 date "2022-02-20" @default.
• W4213307792 modified "2023-10-16" @default.
• W4213307792 title "TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy." @default.
• W4213307792 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.tps582" @default.
• W4213307792 hasPublicationYear "2022" @default.
• W4213307792 type Work @default.
• W4213307792 citedByCount "4" @default.
• W4213307792 countsByYear W42133077922022 @default.
• W4213307792 countsByYear W42133077922023 @default.
• W4213307792 crossrefType "journal-article" @default.
• W4213307792 hasAuthorship W4213307792A5004985848 @default.
• W4213307792 hasAuthorship W4213307792A5007663088 @default.
• W4213307792 hasAuthorship W4213307792A5009459069 @default.
• W4213307792 hasAuthorship W4213307792A5018733361 @default.
• W4213307792 hasAuthorship W4213307792A5019000637 @default.
• W4213307792 hasAuthorship W4213307792A5026717218 @default.
• W4213307792 hasAuthorship W4213307792A5027991868 @default.
• W4213307792 hasAuthorship W4213307792A5036620887 @default.
• W4213307792 hasAuthorship W4213307792A5039540735 @default.
• W4213307792 hasAuthorship W4213307792A5044972820 @default.
• W4213307792 hasAuthorship W4213307792A5051250922 @default.
• W4213307792 hasAuthorship W4213307792A5074756323 @default.
• W4213307792 hasAuthorship W4213307792A5075511405 @default.
• W4213307792 hasAuthorship W4213307792A5083331837 @default.
• W4213307792 hasConcept C121608353 @default.
• W4213307792 hasConcept C126322002 @default.
• W4213307792 hasConcept C141071460 @default.
• W4213307792 hasConcept C143998085 @default.
• W4213307792 hasConcept C2776694085 @default.
• W4213307792 hasConcept C31760486 @default.
• W4213307792 hasConcept C71924100 @default.
• W4213307792 hasConcept C90924648 @default.
• W4213307792 hasConceptScore W4213307792C121608353 @default.
• W4213307792 hasConceptScore W4213307792C126322002 @default.
• W4213307792 hasConceptScore W4213307792C141071460 @default.
• W4213307792 hasConceptScore W4213307792C143998085 @default.
• W4213307792 hasConceptScore W4213307792C2776694085 @default.
• W4213307792 hasConceptScore W4213307792C31760486 @default.
• W4213307792 hasConceptScore W4213307792C71924100 @default.
• W4213307792 hasConceptScore W4213307792C90924648 @default.
• W4213307792 hasFunder F4320308573 @default.
• W4213307792 hasIssue "6_suppl" @default.
• W4213307792 hasLocation W42133077921 @default.
• W4213307792 hasOpenAccess W4213307792 @default.
• W4213307792 hasPrimaryLocation W42133077921 @default.
• W4213307792 hasRelatedWork W2002120878 @default.
• W4213307792 hasRelatedWork W2003938723 @default.
• W4213307792 hasRelatedWork W2024219304 @default.
• W4213307792 hasRelatedWork W2047967234 @default.
• W4213307792 hasRelatedWork W2100029565 @default.
• W4213307792 hasRelatedWork W2118496982 @default.
• W4213307792 hasRelatedWork W2439875401 @default.
• W4213307792 hasRelatedWork W3203829896 @default.
• W4213307792 hasRelatedWork W4238867864 @default.
• W4213307792 hasRelatedWork W2525756941 @default.
• W4213307792 hasVolume "40" @default.
• W4213307792 isParatext "false" @default.
• W4213307792 isRetracted "false" @default.
• W4213307792 workType "article" @default.